Switching from IV to subcutaneous infliximab maintenance therapy is associated with high treatment persistence and a stable ...

South Korean biosimilars developer Celltrion late yesterday announced new post-hoc analyses of its pivotal LIBERTY studies ...

The treatment landscape of Inflammatory Bowel Disease (IBD) has undergone a significant transformation over the past two ...

Many school district leaders1 are committed to integrating the science of reading principles into instruction. However, 60% are dissatisfied with the effectiveness of their current adolescent literacy ...

Applied Policy is pleased to announce the appointment of Linda Rouse O'Neill as Vice President of Health Policy specializing in medical device coverage, coding and reimbursement. O'Neill brings ...

the company has expanded access to ZYMFENTRA® (infliximab-dyyb), the first and only U.S. Food and Drug Administration (FDA)-approved subcutaneous infliximab. With these partnerships Celltrion has ...

SAN FRANCISCO -- More adults with moderate-to-severe Crohn's disease (CD) reached clinical remission after 6 months on risankizumab (Skyrizi) versus ustekinumab (Stelara), according to a head-to-head ...

Biosimilars have also made inroads among generic suppliers. But development is lengthy and expensive. McKinsey estimates that it costs $100 to $300 million to develop a biosimilar and that it takes ...

The subcutaneous formulation of Opdivo Qvantig reduces administration time to three to five minutes, compared to 30 minutes for the IV version. This formulation offers increased convenience, ...